New eczema drug shows promise in early trial
Symptom relief
Recruiting now
This study tests an experimental drug called IBI3002 in 120 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, thickness, and itching better than a placebo over 16 weeks. Participants will be randomly assigned to receive the …
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Symptom relief
Last updated May 04, 2026 16:18 UTC